Using special polymers to improve targeted cancer treatments
Supramolecular polymers for targeted protein degradation
This study is looking at new ways to make cancer treatments more effective by improving how they target and remove harmful proteins in your body, which could lead to better options for patients dealing with cancer.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern Mississippi NIH-funded |
| Lab location | 1 site (Hattiesburg, United States) |
| Project ID | NIH-10690750 on NIH RePORTER |
What this research studies
This research explores innovative methods to enhance targeted protein degradation therapies, which aim to selectively eliminate harmful proteins associated with diseases like cancer. By utilizing advanced synthetic biology techniques and novel supramolecular polymers, the project seeks to improve how these therapies are delivered to cells, ensuring better specificity and internalization. The goal is to overcome current challenges in drug resistance and unlock new therapeutic targets that were previously considered undruggable. Patients may benefit from more effective treatments that can address their specific cancer types.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit drug resistance or have previously been considered untreatable due to the nature of their protein targets.
Not a fit: Patients with early-stage cancers that are easily treatable with existing therapies may not receive significant benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that specifically target and degrade problematic proteins, potentially improving patient outcomes.
How similar studies have performed: Other research has shown promise in using targeted protein degradation strategies, indicating that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Hattiesburg, United States
- University of Southern Mississippi — Hattiesburg, United States (Active)
Researchers
- Principal investigator: Clemons, Tristan — University of Southern Mississippi
- Study coordinator: Clemons, Tristan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.